Carmell Therapeutics Statistics
Share Statistics
Carmell Therapeutics has 30.12M
shares outstanding. The number of shares has increased by 46.44%
in one year.
| Shares Outstanding | 30.12M |
| Shares Change (YoY) | 46.44% |
| Shares Change (QoQ) | 44.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,923 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.72 and the forward
PE ratio is null.
Carmell Therapeutics's PEG ratio is
-0.01.
| PE Ratio | -2.72 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.7 |
| P/FCF Ratio | -5.01 |
| PEG Ratio | -0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Carmell Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.63,
with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.63 |
| Quick Ratio | 1.63 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.25 |
| Interest Coverage | -5.87 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,716,120.78 |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -760.16K |
| Effective Tax Rate | 4.69% |
Stock Price Statistics
The stock price has increased by -90.05% in the
last 52 weeks. The beta is 0.51, so Carmell Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.51 |
| 52-Week Price Change | -90.05% |
| 50-Day Moving Average | 0.25 |
| 200-Day Moving Average | 0.55 |
| Relative Strength Index (RSI) | 30.21 |
| Average Volume (20 Days) | 8,239,948 |
Income Statement
| Revenue | n/a |
| Gross Profit | -124.79K |
| Operating Income | -5.22M |
| Net Income | -15.45M |
| EBITDA | -15.19M |
| EBIT | -15.32M |
| Earnings Per Share (EPS) | -1.46 |
Full Income StatementBalance Sheet
The company has 2.91M in cash and 2.14M in
debt, giving a net cash position of 776.01K.
| Cash & Cash Equivalents | 2.91M |
| Total Debt | 2.14M |
| Net Cash | 776.01K |
| Retained Earnings | -58.5M |
| Total Assets | 2.44M |
| Working Capital | -4.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -8.35M
and capital expenditures -30.47K, giving a free cash flow of -8.38M.
| Operating Cash Flow | -8.35M |
| Capital Expenditures | -30.47K |
| Free Cash Flow | -8.38M |
| FCF Per Share | -0.76 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
